Poliomyelitis

POLIOMYELITIS VACCINES FOR AUSTRALIANS:
INFORMATION FOR IMMUNISATION PROVIDERS

Disease and epidemiology

- Poliomyelitis (polio) is caused by a virus that has three serotypes, referred to as type 1, type 2 and type 3.

- Person-to-person spread of poliovirus is by the faecal–oral route. Typical manifestations of polio are caused when the virus spreads to infect and replicate in the cells of the central nervous system.

- The characteristic and most severe clinical manifestation of polio infection is paralytic polio that usually presents as asymmetrical permanent paralysis of the legs.

- Australia was declared polio-free by the World Health Organization in 2000.

Who should be vaccinated

- Inactivated polio vaccine (IPV) is recommended and funded under the National Immunisation Program as a primary schedule of 3 doses at 2, 4 and 6 months of age. A booster dose is recommended at 4 years of age.

- Unvaccinated adults are recommended a schedule of 3 doses at 1–2 month intervals.

- A booster dose every 10 years is desirable for certain groups who are at continued risk of polio infection.

Vaccines

- Since 2005, IPV is used for all doses of polio vaccine in Australia.

- IPV-containing combination vaccines recommended for use in children 2 months to <10 years of age are Infanrix® hexa, Pediacel®, Infanrix® IPV and Quadracel®.

- IPV-containing combination vaccines recommended for use in persons ≥10 years of age are Adacel® Polio and Boostrix®-IPV.

- An IPV that only contains inactivated poliovirus, IPOL®, is recommended for use in children from 2 months of age and adults, in circumstances where only IPV vaccination is required.
**The disease**

Poliomyelitis (polio), historically called infantile paralysis, is an infectious disease caused by the poliovirus. Poliovirus is a member of the enterovirus subgroup of the Picornaviridae family and has three serotypes: type 1, type 2 and type 3. Immunity to one serotype does not provide significant protection against the other serotypes.1,2

Poliovirus transmission is primarily by the faecal–oral, or occasionally oral–oral, route. Once in the gastrointestinal tract, the virus invades the local lymphoid tissues and, in a minority of cases, enters the bloodstream and spreads to the central nervous system. The virus may also spread to the central nervous system along the peripheral nerves. The incubation period for polio infection is usually between 7 and 14 days but may range from 2 to 35 days. By 3–5 days after exposure, the virus can be isolated in the blood, throat and faeces. The virus continues to be excreted in the stools for several weeks after infection.1,2

Clinical manifestations of polio can vary and they are categorised according to severity. Acute flaccid paralysis (AFP) is a common acute manifestation of polio (refer also to Surveillance for acute flaccid paralysis). The majority (up to 95%) of polio infections are asymptomatic. Those infected who don’t show any symptoms shed the virus in their stools and, therefore, are able to transmit the virus to others. In polio endemic areas, persons with asymptomatic infections, particularly children, act as the main reservoir of polio infection.1,2

Rarely (in less than 1% of polio infections), the virus invades and damages or completely destroys the motor neurons of anterior horn cells of the spinal cord and brain stem. This form, known as paralytic polio, is the most severe and typical manifestation of poliomyelitis. Depending on the extent of central nervous system damage, paralytic polio is classified into spinal, bulbar and bulbospinal forms which have different clinical presentations.1,3

Most patients, even with paralytic polio, recover completely and, in most others, muscle function returns to some degree. However, paralysis or weakness that persists 12 months after the onset is usually permanent.1,2 Among those paralysed, 5–10% die when their breathing muscles become paralysed.4 In the past, these patients were immobilised inside negative pressure mechanical ventilators to regulate their breathing and keep them alive. These huge metal cylinders that were called ‘iron lungs’ became a symbol of polio.5

Postpolio syndrome (PPS) is a complex of neuromuscular symptoms that usually occurs 15 years or more after the acute illness in many survivors of paralytic polio. The prevalence of PPS has been reported to range from 15% to 80% of all people with previous paralytic polio. Diagnosis of PPS is based on clinical signs and symptoms that include muscle weakness or decreased muscle endurance, with or without muscle atrophy or muscle and joint pain. There are no diagnostic tests available for PPS and diagnosis is based on exclusion of other causes for the new symptoms. PPS is not an infectious process and persons who develop PPS do not shed poliovirus.5,7

**Polio vaccines in Australia**

The trivalent inactivated polio vaccine (IPV), which includes all three poliovirus serotypes, was first registered in Australia in 1955. Routine vaccination with IPV on the National Immunisation Program (NIP) started in 1956 and continued until 1966 when it was replaced by live attenuated oral polio vaccine (OPV). OPV has several advantages over IPV in providing mass protection against the transmission of wild poliovirus. OPV induces a local immune response in the intestines, the primary site for poliovirus multiplication, which provides local resistance to subsequent infection with wild poliovirus and also reduces the risk of excretion of the virus. In addition, the virus in OPV can be transmitted from recent vaccinees to their non-immunised contacts; in turn providing protection to the community.6 However, there is a risk of the attenuated vaccine virus strains in OPV reverting to forms that are capable of causing vaccine-associated paralytic poliomyelitis (VAPP), which is clinically indistinguishable from paralytic polio caused by wild poliovirus. (Refer also to Epidemiology.) OPV virus may also gain the ability to circulate in communities for long periods of time (referred to as vaccine-derived polioviruses, VDPVs).

In comparison to OPV, IPV does not contain live virus and, therefore, cannot cause VAPP. An enhanced potency IPV first became available internationally in 1988 and gradually replaced OPV in many countries. The change from OPV to IPV was implemented in Australia in November 2005 as part of combination vaccines also containing antigens against a number of other diseases.

Vaccination coverage for polio in Australia, including the Torres Strait Islands, is generally high. In 2013, all states and territories had vaccination coverage of greater than 90% for all children at 12 months of age and at least 93% at 2 years of age.9 However, vaccination coverage varies widely across Australia by geographical area, age group and Indigenous status.
Epidemiology
The World Health Organization (WHO) has been committed to the eradication of polio since 1988 and polio cases have decreased by over 99% since that time. Eradication targets were set for 2005 and again in 2010 and most recently the WHO announced the Polio Eradication and Endgame Strategic Plan 2013–2018. Eradication would mean the incidence of polio was permanently zero and intervention measures such as vaccination would no longer be needed. In 2015, wild poliovirus type 2 was declared eradicated worldwide and type 3 had not been detected for nearly 3 years, moving the globe closer to the goal of eradication. Since 2014, only two countries have reported polio cases caused by wild poliovirus type 1 (Afghanistan and Pakistan). Current information related to the global status of polio is available at [www.polioeradication.org](http://www.polioeradication.org).

Until global eradication of polio is achieved, all countries are at risk of polio infection, particularly with the ease of global travel. For example, in 2007, wild poliovirus type 1 was isolated from a young man in Australia who had recently arrived from Pakistan. Due to the protective effect of high polio vaccine coverage in Australia, the imported virus did not spread any further in the community. The WHO estimates that from 2003 to 2014, there were 191 new importation events of wild poliovirus into previously polio-free countries, resulting in 3,763 reported cases of paralytic polio in 43 countries. The international spread of polio in 2014 constituted a Public Health Emergency of International Concern under the International Health Regulations (2005), resulting in temporary polio vaccination requirements to reduce the risk of international spread of polioviruses from infected areas into previously polio-free countries. However, documented evidence of polio vaccination is not routinely required for travellers under International Health Regulations.

Polio has been a notifiable disease in Australia since 1922. The highest recorded incidence of polio in the country (39.1 per 100,000 population) was in 1938. A dramatic decline in polio notifications was seen after the introduction of routine vaccination with IPV in 1956, with the last polio epidemic in 1961–1962. As expected, sustained high coverage with OPV following its introduction in 1966 led to cessation of indigenous transmission of wild poliovirus infections in Australia, with the last reported case of locally acquired wild poliovirus in 1972. In 1986, there was a case of polio reported in a 22-year-old that was initially thought to be due to wild poliovirus but was later confirmed as VAPP. The last reported case of VAPP in Australia occurred in an unvaccinated mother of a recently vaccinated infant in 1995.

In October 2000, Australia together with the other 36 countries in the Western Pacific Region was declared ‘polio-free’ by the WHO. Certification of polio-free status is confirmation of the interruption of indigenous poliovirus transmission and containment of wild poliovirus in the country.

Surveillance for acute flaccid paralysis
In addition to maintaining high polio vaccine coverage, adequate surveillance for cases of AFP is also an important defence against the continuing threat of polio infection. AFP is a highly sensitive indicator of polio. However, because AFP has a number of other possible causes, adequate active surveillance and classification of all cases of AFP in children 0–15 years of age is recommended by the WHO in order to detect suspected cases of polio. This criterion needs to be satisfied for certification and maintenance of polio-free status by the WHO.

The Australian Paediatric Surveillance Unit (APSU) has conducted surveillance for AFP since 1993. APSU relies on reporting by approximately 1,350 paediatricians around Australia. In 2007, in collaboration with NCIRS, APSU developed a hospital-based surveillance system, Paediatric Active Enhanced Disease Surveillance (PAEDS), which relies on active identification of AFP cases by specialist surveillance nurses in five children’s hospitals across the country. More information on PAEDS is available at [www.paeds.edu.au](http://www.paeds.edu.au).

Who should be vaccinated

Infants and children
Polio vaccination is recommended and funded under the National Immunisation Program as a 3-dose primary course at 2, 4 and 6 months of age, using either IPV (IPOL®) or IPV-containing combination vaccine, unless contraindicated (refer to [Contraindications/precautions](#)). The 1st dose of an IPV-containing vaccine can be given as early as 6 weeks of age. If the 1st dose is given at 6 weeks of age, the next scheduled doses should still be given at 4 months and 6 months of age.

A booster dose of IPV (IPOL®) or IPV-containing vaccine is recommended at 4 years of age but can be given as early as 3.5 years of age. This is commonly provided in combination with diphtheria, tetanus and acellular pertussis as DTPa-IPV.

If any of the doses recommended as part of the infant primary schedule have been missed, advice on planning...
catch-up can be found in *The Australian Immunisation Handbook* (Chapter 2.1).²⁹

**Adults**

No adult should remain unvaccinated against polio. If an adult was not vaccinated against polio during childhood, a 3-dose primary course of IPV (IPOL®) or IPV-containing vaccine is recommended. Advice on planning catch-up can be found in *The Australian Immunisation Handbook* (Chapter 2.1).²⁹

**Special risk groups**

A booster dose every 10 years is desirable for adults at continued risk of polio infection, such as:

- travellers to areas or countries where polio is epidemic or endemic; refer also to WHO recommendations on vaccinations for travellers.³⁰
- healthcare workers, including laboratory workers, in possible contact with polio cases or poliovirus.

Reduced antigen diphtheria-tetanus-acellular pertussis-IPV (dTpa-IPV) combination vaccines can be used where otherwise indicated.

**Vaccines**

**Formulations currently registered in Australia**

For any age group

IPOL® (IPV; inactivated poliovirus)

For children aged <10 years

Infanrix™ hexa (dTpa-hevB-IPV-Hib), Pediace® (dTpa-IPV-Hib), Infanrix® IPV (dTPa-IPV) and Quadrace® (dTPa-IPV)

Adults, adolescents and children aged ≥10 years

Adacel® Polio (dTpa-IPV) and Boostrix®-IPV (dTpa-IPV)

**Interchangeability of oral and inactivated polio vaccines**

Oral polio vaccine (OPV) is no longer in use in Australia. OPV and IPV are interchangeable. Children commenced on OPV should complete their polio vaccination schedule using IPV (IPOL®) or IPV-containing vaccines.

**Vaccine efficacy/effectiveness**

IPV is highly effective in producing immunity to poliovirus and protection from paralytic polio. After 2 doses of the vaccine, over 90% of recipients develop protective antibodies to all three types of poliovirus. After 3 doses, at least 99% of recipients will have protection against the disease. Protection against paralytic disease correlates with the presence of antibodies against poliovirus.¹

The exact duration of protection from IPV is not known with certainty. However, evidence shows that IPV provides protection for many years after a complete course.¹

**Vaccine safety**

Inactivated polio vaccines can be safely administered to persons with impaired immunity and to persons living with someone with impaired immunity.

IPV (IPOL®) and IPV-containing vaccines may cause erythema, pain, and induration at the injection site. Other symptoms reported following administration of IPV (IPOL®) or IPV-containing vaccines in young babies include fever, crying and decreased appetite.

**Contraindications/precautions**

The only absolute contraindications to IPV (IPOL®) or IPV-containing vaccines are anaphylaxis following a previous dose of the vaccine, or anaphylaxis following any component of the vaccine.

**Pregnancy and breastfeeding**

IPV (IPOL®) or IPV-containing vaccines are not routinely recommended for pregnant or breastfeeding women, but can be given where vaccination is considered necessary (e.g. for travel to endemic countries). Further advice on the vaccination of women who are planning pregnancy, pregnant or breastfeeding, and preterm infants can be found in *The Australian Immunisation Handbook* (Chapter 3.3).²⁹

**Additional resources for primary medical care/vaccination providers**


**References**


